Patents by Inventor Jens HUKELMANN

Jens HUKELMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240075118
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 7, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240075119
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2023
    Publication date: March 7, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240067697
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO:1 to SEQ ID NO:113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 18, 2023
    Publication date: February 29, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
    Patent number: 11904003
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: February 20, 2024
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
  • Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
    Patent number: 11891427
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: February 6, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Lena Wullkopf, Christoph Schraeder, Jens Fritsche, Daniel Johannes Kowalewski, Michael Roemer, Oliver Schoor
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240024440
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 11, 2023
    Publication date: January 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240024441
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016907
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016906
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016913
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016910
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016911
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016909
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 18, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016912
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20230414734
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 28, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
    Patent number: 11833195
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: December 5, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20230338488
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 23, 2023
    Publication date: October 26, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20230285525
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 14, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20230257442
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 24, 2023
    Publication date: August 17, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
  • ANTIGEN BINDING PROTEINS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20230190874
    Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Jens FRITSCHE, Oliver SCHOOR, Frank SCHWOEBEL, Lena Katharina FREUDENMANN